BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol 2020;13:104. [PMID: 32723346 DOI: 10.1186/s13045-020-00937-8] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 19.5] [Reference Citation Analysis]
Number Citing Articles
1 Mola S, Pinton G, Erreni M, Corazzari M, De Andrea M, Grolla AA, Martini V, Moro L, Porta C. Inhibition of the Histone Methyltransferase EZH2 Enhances Protumor Monocyte Recruitment in Human Mesothelioma Spheroids. Int J Mol Sci 2021;22:4391. [PMID: 33922336 DOI: 10.3390/ijms22094391] [Reference Citation Analysis]
2 Alarcón T, Sardanyés J, Guillamon A, Menendez JA. Bivalent chromatin as a therapeutic target in cancer: An in silico predictive approach for combining epigenetic drugs. PLoS Comput Biol 2021;17:e1008408. [PMID: 34153035 DOI: 10.1371/journal.pcbi.1008408] [Reference Citation Analysis]
3 Zhou C, He A, Kang Q, Li C, Liu T, Cai W, Fang L, Ma S. Development of a UPLC-MS/MS method for determination of a dual EZH1/2 inhibitor UNC1999 in rat plasma. Bioanalysis 2022;14:67-74. [PMID: 34841882 DOI: 10.4155/bio-2021-0227] [Reference Citation Analysis]
4 Czegle I, Gray AL, Wang M, Liu Y, Wang J, Wappler-guzzetta EA. Mitochondria and Their Relationship with Common Genetic Abnormalities in Hematologic Malignancies. Life 2021;11:1351. [DOI: 10.3390/life11121351] [Reference Citation Analysis]
5 Xing CY, Zhang YZ, Hu W, Zhao LY. LINC00313 facilitates osteosarcoma carcinogenesis and metastasis through enhancing EZH2 mRNA stability and EZH2-mediated silence of PTEN expression. Cell Mol Life Sci 2022;79:382. [PMID: 35751755 DOI: 10.1007/s00018-022-04376-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zhou J, Yang Y, Wang YL, Zhao Y, Ye WJ, Deng SY, Lang JY, Lu S. Enhancer of zeste homolog 2 contributes to apoptosis by inactivating janus kinase 2/ signal transducer and activator of transcription signaling in inflammatory bowel disease. World J Gastroenterol 2021; 27(22): 3073-3084 [PMID: 34168409 DOI: 10.3748/wjg.v27.i22.3073] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 He L, Lomberk G. Collateral Victim or Rescue Worker?-The Role of Histone Methyltransferases in DNA Damage Repair and Their Targeting for Therapeutic Opportunities in Cancer. Front Cell Dev Biol 2021;9:735107. [PMID: 34869318 DOI: 10.3389/fcell.2021.735107] [Reference Citation Analysis]
8 He ZC, Yang F, Guo LL, Wei Z, Dong X. LncRNA TP73-AS1 promotes the development of Epstein-Barr virus associated gastric cancer by recruiting PRC2 complex to regulate WIF1 methylation. Cell Signal 2021;:110094. [PMID: 34314802 DOI: 10.1016/j.cellsig.2021.110094] [Reference Citation Analysis]
9 Nepali K, Liou JP. Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends. J Biomed Sci 2021;28:27. [PMID: 33840388 DOI: 10.1186/s12929-021-00721-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhou Q, Chen X, He H, Peng S, Zhang Y, Zhang J, Cheng L, Liu S, Huang M, Xie R, Lin T, Huang J. WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer. Theranostics 2021;11:4809-24. [PMID: 33754029 DOI: 10.7150/thno.55814] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
11 Taylor-papadimitriou J, Burchell JM. Histone Methylases and Demethylases Regulating Antagonistic Methyl Marks: Changes Occurring in Cancer. Cells 2022;11:1113. [DOI: 10.3390/cells11071113] [Reference Citation Analysis]
12 Xu W, Li C, Ma B, Lu Z, Wang Y, Jiang H, Luo Y, Yang Y, Wang X, Liao T, Ji Q, Wang Y, Wei W. Identification of Key Functional Gene Signatures Indicative of Dedifferentiation in Papillary Thyroid Cancer. Front Oncol 2021;11:641851. [PMID: 33996555 DOI: 10.3389/fonc.2021.641851] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Duan YC, Zhang SJ, Shi XJ, Jin LF, Yu T, Song Y, Guan YY. Research progress of dual inhibitors targeting crosstalk between histone epigenetic modulators for cancer therapy. Eur J Med Chem 2021;222:113588. [PMID: 34107385 DOI: 10.1016/j.ejmech.2021.113588] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Yao W, Wang J, Zhu L, Jia X, Xu L, Tian X, Hu S, Wu S, Wei L. Epigenetic Regulator KDM4D Restricts Tumorigenesis via Modulating SYVN1/HMGB1 Ubiquitination Axis in Esophageal Squamous Cell Carcinoma. Front Oncol 2021;11:761346. [PMID: 34820329 DOI: 10.3389/fonc.2021.761346] [Reference Citation Analysis]
15 Zhu G, Xia H, Tang Q, Bi F. An epithelial-mesenchymal transition-related 5-gene signature predicting the prognosis of hepatocellular carcinoma patients. Cancer Cell Int 2021;21:166. [PMID: 33712026 DOI: 10.1186/s12935-021-01864-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
16 Su R, Wu X, Tao L, Wang C. The role of epigenetic modifications in Colorectal Cancer Metastasis. Clin Exp Metastasis 2022. [PMID: 35429301 DOI: 10.1007/s10585-022-10163-w] [Reference Citation Analysis]
17 Wang T, Yang L, Liang Z, Bai L, Pei H, Zhang T, Wu L, Wang L, Wang X, You X, He C. Pulsed electromagnetic fields attenuate glucocorticoid-induced bone loss by targeting senescent LepR+ bone marrow mesenchymal stromal cells. Materials Science and Engineering: C 2021. [DOI: 10.1016/j.msec.2021.112635] [Reference Citation Analysis]
18 Chen B, Dong C, Wang F, Wu J. Knockdown of NIR Suppresses Breast Cancer Cell Proliferation via Promoting FOXO3. Onco Targets Ther 2021;14:637-51. [PMID: 33519211 DOI: 10.2147/OTT.S287464] [Reference Citation Analysis]
19 Shin DS, Park K, Garon E, Dubinett S. Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer. Seminars in Oncology 2022. [DOI: 10.1053/j.seminoncol.2022.06.005] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 April-Monn SL, Andreasi V, Schiavo Lena M, Sadowski MC, Kim-Fuchs C, Buri MC, Ketkar A, Maire R, Di Domenico A, Schrader J, Muffatti F, Doglioni C, Partelli S, Falconi M, Perren A, Marinoni I. EZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs). Cancers (Basel) 2021;13:5014. [PMID: 34638497 DOI: 10.3390/cancers13195014] [Reference Citation Analysis]
21 Rinott Mizrahi G, Williams I, Azad A, Lawrentschuk N. Genetics of neuroendocrine prostate cancer: recent progress in genetic understanding is translating into therapeutic opportunities. Current Opinion in Urology 2022;Publish Ahead of Print. [DOI: 10.1097/mou.0000000000001015] [Reference Citation Analysis]
22 Chang L, Zhou R. Histone methyltransferase EZH2 in proliferation, invasion, and migration of fibroblast-like synoviocytes in rheumatoid arthritis. J Bone Miner Metab 2022. [PMID: 35083555 DOI: 10.1007/s00774-021-01299-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Wen J, Wan L, Dong X. The prognostic value of autophagy related genes with potential protective function in Ewing sarcoma. BMC Bioinformatics 2022;23:306. [PMID: 35902797 DOI: 10.1186/s12859-022-04849-x] [Reference Citation Analysis]
24 Xia J, Li J, Tian L, Ren X, Liu C, Liang C. Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure–Activity Relationships Insights and Evolution Prospects. J Med Chem . [DOI: 10.1021/acs.jmedchem.2c00047] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Bremer SCB, Bittner G, Elakad O, Dinter H, Gaedcke J, König AO, Amanzada A, Ellenrieder V, Freiherr von Hammerstein-Equord A, Ströbel P, Bohnenberger H. Enhancer of Zeste Homolog 2 (EZH2) Is a Marker of High-Grade Neuroendocrine Neoplasia in Gastroenteropancreatic and Pulmonary Tract and Predicts Poor Prognosis. Cancers (Basel) 2022;14:2828. [PMID: 35740494 DOI: 10.3390/cancers14122828] [Reference Citation Analysis]
26 Li C, Song J, Guo Z, Gong Y, Zhang T, Huang J, Cheng R, Yu X, Li Y, Chen L, Ma X, Sun Y, Wang Y, Xue L. EZH2 Inhibitors Suppress Colorectal Cancer by Regulating Macrophage Polarization in the Tumor Microenvironment. Front Immunol 2022;13:857808. [DOI: 10.3389/fimmu.2022.857808] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Camacho-Ordonez N, Ballestar E, Timmers HTM, Grimbacher B. What can clinical immunology learn from inborn errors of epigenetic regulators? J Allergy Clin Immunol. 2021;147:1602-1618. [PMID: 33609625 DOI: 10.1016/j.jaci.2021.01.035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Ding S, Wang X, Lv D, Tao Y, Liu S, Chen C, Huang Z, Zheng S, Wei Y, Kang T, Xia Y. EBF3 reactivation by inhibiting the EGR1/EZH2/HDAC9 complex promotes metastasis via transcriptionally enhancing vimentin in nasopharyngeal carcinoma. Cancer Lett 2021;527:49-65. [PMID: 34906623 DOI: 10.1016/j.canlet.2021.12.010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Chen Z, Yuan L, Li X, Yu J, Xu Z. BMP2 inhibits cell proliferation by downregulating EZH2 in gastric cancer. Cell Cycle 2022;:1-11. [PMID: 35856444 DOI: 10.1080/15384101.2022.2092819] [Reference Citation Analysis]
30 Chen Z, Lin X, Wan Z, Xiao M, Ding C, Wan P, Li Q, Zheng S. High Expression of EZH2 Mediated by ncRNAs Correlates with Poor Prognosis and Tumor Immune Infiltration of Hepatocellular Carcinoma. Genes 2022;13:876. [DOI: 10.3390/genes13050876] [Reference Citation Analysis]
31 Chen S, Gu J, Zhang Q, Hu Y, Ge Y. Development of Biomarker Signatures Associated with Anoikis to Predict Prognosis in Endometrial Carcinoma Patients. J Oncol 2021;2021:3375297. [PMID: 34992654 DOI: 10.1155/2021/3375297] [Reference Citation Analysis]
32 Benjaskulluecha S, Boonmee A, Pattarakankul T, Wongprom B, Klomsing J, Palaga T. Screening of compounds to identify novel epigenetic regulatory factors that affect innate immune memory in macrophages. Sci Rep 2022;12:1912. [PMID: 35115604 DOI: 10.1038/s41598-022-05929-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Wang J, Zhao J, Hu P, Gao L, Tian S, He Z. Long Non-coding RNA HOTAIR in Central Nervous System Disorders: New Insights in Pathogenesis, Diagnosis, and Therapeutic Potential. Front Mol Neurosci 2022;15:949095. [DOI: 10.3389/fnmol.2022.949095] [Reference Citation Analysis]
34 Peng W, Tang W, Li J, He R, Luo J, Chen Z, Zeng J, Hu X, Zhong J, Li Y, Ma F, Xie T, Huang S, Ge L. Downregulation of the enhancer of zeste homolog 1 transcriptional factor predicts poor prognosis of triple-negative breast cancer patients. PeerJ 2022;10:e13708. [DOI: 10.7717/peerj.13708] [Reference Citation Analysis]
35 Iizuka T, Nagano H, Nomura K, Hiramatsu M, Motoi N, Mun M, Ishikawa Y. The combined use of long non-coding RNA HOTAIR and polycomb group protein EZH2 as a prognostic marker of lung adenocarcinoma. Cancer Treatment and Research Communications 2022;31:100541. [DOI: 10.1016/j.ctarc.2022.100541] [Reference Citation Analysis]
36 Cui Y, Li H, Zhan H, Han T, Dong Y, Tian C, Guo Y, Yan F, Dai D, Liu P. Identification of Potential Biomarkers for Liver Cancer Through Gene Mutation and Clinical Characteristics. Front Oncol 2021;11:733478. [PMID: 34604069 DOI: 10.3389/fonc.2021.733478] [Reference Citation Analysis]
37 Jenseit A, Camgöz A, Pfister SM, Kool M. EZHIP: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma. Acta Neuropathol 2022;143:1-13. [PMID: 34762160 DOI: 10.1007/s00401-021-02382-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
38 Zhai X, Li LS, Zhou YD, Ji WY, Chen H, Xiao H, Liang P. EZH2 regulates the malignancy of human glioblastoma cells via modulation of Twist mRNA stability. Eur J Pharmacol 2021;904:174177. [PMID: 34015321 DOI: 10.1016/j.ejphar.2021.174177] [Reference Citation Analysis]
39 Li T, Yu C, Zhuang S. Histone Methyltransferase EZH2: A Potential Therapeutic Target for Kidney Diseases. Front Physiol 2021;12:640700. [PMID: 33679454 DOI: 10.3389/fphys.2021.640700] [Reference Citation Analysis]
40 Yang J, Weisberg EL, Qi S, Ni W, Mei H, Wang Z, Meng C, Zhang S, Hou M, Qi Z, Wang A, Jiang Y, Jiang Z, Huang T, Liu Q, Magin RS, Doherty L, Wang W, Liu J, Buhrlage SJ, Liu Q, Griffin JD. Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2. Leukemia 2022. [PMID: 35034955 DOI: 10.1038/s41375-021-01494-w] [Reference Citation Analysis]
41 Meng X, Lou QY, Yang WY, Wang YR, Chen R, Wang L, Xu T, Zhang L. The role of non-coding RNAs in drug resistance of oral squamous cell carcinoma and therapeutic potential. Cancer Commun (Lond) 2021. [PMID: 34289530 DOI: 10.1002/cac2.12194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Wang C, Zhang Y, Wang J, Xing D. VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives. Eur J Med Chem 2022;227:113906. [PMID: 34656901 DOI: 10.1016/j.ejmech.2021.113906] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
43 Garner IM, Brown R. Is There a Role for Epigenetic Therapies in Modulating DNA Damage Repair Pathways to Enhance Chemotherapy and Overcome Drug Resistance? Cancers 2022;14:1533. [DOI: 10.3390/cancers14061533] [Reference Citation Analysis]
44 Hu M, Ma Q, Liu B, Wang Q, Zhang T, Huang T, Lv Z. Long Non-Coding RNAs in the Pathogenesis of Diabetic Kidney Disease. Front Cell Dev Biol 2022;10:845371. [DOI: 10.3389/fcell.2022.845371] [Reference Citation Analysis]
45 Dong Y, Gao Y, Xie T, Liu H, Zhan X, Xu Y. miR-101-3p Serves as a Tumor Suppressor for Renal Cell Carcinoma and Inhibits Its Invasion and Metastasis by Targeting EZH2. Biomed Res Int 2021;2021:9950749. [PMID: 34307682 DOI: 10.1155/2021/9950749] [Reference Citation Analysis]
46 Milán-Rois P, Quan A, Slack FJ, Somoza Á. The Role of LncRNAs in Uveal Melanoma. Cancers (Basel) 2021;13:4041. [PMID: 34439196 DOI: 10.3390/cancers13164041] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Leng XY, Fan H. Progress in research of EZH2 in digestive system tumors. Shijie Huaren Xiaohua Zazhi 2021; 29(5): 242-247 [DOI: 10.11569/wcjd.v29.i5.242] [Reference Citation Analysis]
48 Menez S, Ju W, Menon R, Moledina DG, Thiessen Philbrook H, McArthur E, Jia Y, Obeid W, Mansour SG, Koyner JL, Shlipak MG, Coca SG, Garg AX, Bomback AS, Kellum JA, Kretzler M, Parikh CR; Translational Research Investigating Biomarker Endpoints in AKI (TRIBE-AKI) Consortium and the Kidney Precision Medicine Project. Urinary EGF and MCP-1 and risk of CKD after cardiac surgery. JCI Insight 2021;6:147464. [PMID: 33974569 DOI: 10.1172/jci.insight.147464] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
49 Naert T, Tulkens D, Van Nieuwenhuysen T, Przybyl J, Demuynck S, van de Rijn M, Al-Jazrawe M, Alman BA, Coucke PJ, De Leeneer K, Vanhove C, Savvides SN, Creytens D, Vleminckx K. CRISPR-SID: Identifying EZH2 as a druggable target for desmoid tumors via in vivo dependency mapping. Proc Natl Acad Sci U S A 2021;118:e2115116118. [PMID: 34789568 DOI: 10.1073/pnas.2115116118] [Reference Citation Analysis]
50 Liu Z, Pu Y, Bao Y, He S. Investigation of Potential Molecular Biomarkers for Diagnosis and Prognosis of AFP-Negative HCC. Int J Gen Med 2021;14:4369-80. [PMID: 34408477 DOI: 10.2147/IJGM.S323868] [Reference Citation Analysis]
51 Lim HJ, Kim M. EZH2 as a Potential Target for NAFLD Therapy. Int J Mol Sci 2020;21:E8617. [PMID: 33207561 DOI: 10.3390/ijms21228617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Liao M, Sun X, Gao S, Zhang Y. A Class of Protein-Coding RNAs Binds to Polycomb Repressive Complex 2 and Alters Histone Methylation. Front Oncol 2021;11:739830. [PMID: 34804929 DOI: 10.3389/fonc.2021.739830] [Reference Citation Analysis]
53 Liu J, Pan C, Lu R, Zhang S. Long noncoding RNA ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1 antisense RNA 1 recruits enhancer of zeste 2 polycomb repressive complex 2 subunit to promote the proliferation, migration and invasion of lung adenocarcinoma cells. Bioengineered 2022;13:7868-80. [PMID: 35291911 DOI: 10.1080/21655979.2022.2050968] [Reference Citation Analysis]
54 Xu L, Zhang J, Sun J, Hou K, Yang C, Guo Y, Liu X, Kalvakolanu DV, Zhang L, Guo B. Epigenetic regulation of cancer stem cells: Shedding light on the refractory/relapsed cancers. Biochemical Pharmacology 2022. [DOI: 10.1016/j.bcp.2022.115110] [Reference Citation Analysis]
55 Xu WD, Huang Q, Huang AF. Emerging role of EZH2 in rheumatic diseases: A comprehensive review. Int J Rheum Dis 2022. [PMID: 35933601 DOI: 10.1111/1756-185X.14416] [Reference Citation Analysis]
56 Passeri T, Dahmani A, Masliah-Planchon J, Naguez A, Michou M, El Botty R, Vacher S, Bouarich R, Nicolas A, Polivka M, Franck C, Schnitzler A, Némati F, Roman-Roman S, Bourdeaut F, Adle-Biassette H, Mammar H, Froelich S, Bièche I, Decaudin D. Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma Xenograft. Cancers (Basel) 2022;14:1486. [PMID: 35326637 DOI: 10.3390/cancers14061486] [Reference Citation Analysis]
57 Prado G, Kaestner CL, Licht JD, Bennett RL. Targeting epigenetic mechanisms to overcome venetoclax resistance. Biochim Biophys Acta Mol Cell Res 2021;1868:119047. [PMID: 33945824 DOI: 10.1016/j.bbamcr.2021.119047] [Reference Citation Analysis]
58 Qian C, Yang C, Tang Y, Zheng W, Zhou Y, Zhang S, Song M, Cheng P, Wei Z, Zhong C, Wan L, Wang A, Zhao Y, Lu Y. Pharmacological manipulation of Ezh2 with salvianolic acid B results in tumor vascular normalization and synergizes with cisplatin and T cell-mediated immunotherapy. Pharmacol Res 2022;182:106333. [PMID: 35779815 DOI: 10.1016/j.phrs.2022.106333] [Reference Citation Analysis]
59 Zheng J, Chen L. Non-coding RNAs-EZH2 regulatory mechanisms in cervical cancer: The current state of knowledge. Biomed Pharmacother 2021;146:112123. [PMID: 34915417 DOI: 10.1016/j.biopha.2021.112123] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
60 Borkiewicz L. Histone 3 Lysine 27 Trimethylation Signature in Breast Cancer. Int J Mol Sci 2021;22:12853. [PMID: 34884658 DOI: 10.3390/ijms222312853] [Reference Citation Analysis]
61 Dobre EG, Constantin C, Costache M, Neagu M. Interrogating Epigenome toward Personalized Approach in Cutaneous Melanoma. J Pers Med 2021;11:901. [PMID: 34575678 DOI: 10.3390/jpm11090901] [Reference Citation Analysis]
62 Katainen R, Donner I, Räisänen M, Berta D, Kuosmanen A, Kaasinen E, Hietala M, Aaltonen LA. Novel germline variant in the histone demethylase and transcription regulator KDM4C induces a multi-cancer phenotype. J Med Genet 2021:jmedgenet-2021-107747. [PMID: 34281993 DOI: 10.1136/jmedgenet-2021-107747] [Reference Citation Analysis]
63 Liu K, Zhu K, Zhang H. An overview of the development of EED inhibitors to disable the PRC2 function. RSC Med Chem 2022;13:39-53. [DOI: 10.1039/d1md00274k] [Reference Citation Analysis]
64 Nylund P, Atienza Párraga A, Haglöf J, De Bruyne E, Menu E, Garrido-Zabala B, Ma A, Jin J, Öberg F, Vanderkerken K, Kalushkova A, Jernberg-Wiklund H. A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma. Cell Death Dis 2021;12:167. [PMID: 33579905 DOI: 10.1038/s41419-021-03447-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
65 Yin X, Li Y, Wang H, Jia T, Wang E, Luo Y, Wei Y, Qin Z, Ma X. Small cell lung cancer transformation: From pathogenesis to treatment. Semin Cancer Biol 2022:S1044-579X(22)00062-1. [PMID: 35276343 DOI: 10.1016/j.semcancer.2022.03.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
66 Drula R, Iluta S, Gulei D, Iuga C, Dima D, Ghiaur G, Buzoianu AD, Ciechanover A, Tomuleasa C. Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML. Blood Rev 2022;:100971. [PMID: 35595613 DOI: 10.1016/j.blre.2022.100971] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Huang S, Gong N, Li J, Hong M, Li L, Zhang L, Zhang H. The role of ncRNAs in neuroblastoma: mechanisms, biomarkers and therapeutic targets. Biomark Res 2022;10:18. [PMID: 35392988 DOI: 10.1186/s40364-022-00368-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Liu CS, Toth R, Bakr A, Goyal A, Islam MS, Breuer K, Mayakonda A, Lin YY, Stepper P, Jurkowski TP, Veldwijk MR, Sperk E, Herskind C, Lutsik P, Weichenhan D, Plass C, Schmezer P, Popanda O. Epigenetic Modulation of Radiation-Induced Diacylglycerol Kinase Alpha Expression Prevents Pro-Fibrotic Fibroblast Response. Cancers (Basel) 2021;13:2455. [PMID: 34070078 DOI: 10.3390/cancers13102455] [Reference Citation Analysis]
69 Zhang Y, Cui J, Wan W, Liu J. Multimodal Imaging under Artificial Intelligence Algorithm for the Diagnosis of Liver Cancer and Its Relationship with Expressions of EZH2 and p57. Comput Intell Neurosci 2022;2022:4081654. [PMID: 35321452 DOI: 10.1155/2022/4081654] [Reference Citation Analysis]
70 Li J, Gao W, Zhao Z, Li Y, Yang L, Wei W, Ren F, Li Y, Yu Y, Duan W, Li J, Dai B, Guo R. Ginsenoside Rg1 Reduced Microglial Activation and Mitochondrial Dysfunction to Alleviate Depression-Like Behaviour Via the GAS5/EZH2/SOCS3/NRF2 Axis. Mol Neurobiol 2022. [PMID: 35230663 DOI: 10.1007/s12035-022-02740-7] [Reference Citation Analysis]
71 Zhang L, Liu F, Wu L, Fu S, Xing L, Zhang L, Wang X, Wang Y. Disorder of three‐dimensional chromosome structure plays a role in carcinogenesis. Clinical and Translational Dis 2021;1. [DOI: 10.1002/ctd2.17] [Reference Citation Analysis]
72 Touboul R, Baritaki S, Zaravinos A, Bonavida B. RKIP Pleiotropic Activities in Cancer and Inflammatory Diseases: Role in Immunity. Cancers (Basel) 2021;13:6247. [PMID: 34944867 DOI: 10.3390/cancers13246247] [Reference Citation Analysis]
73 Pan R, Yu D, Hu J, Yang X, Wang C, Zhang L, Xue P, Sun J, Zhang X, Cai W. SFMBT1 facilitates colon cancer cell metastasis and drug resistance combined with HMG20A. Cell Death Discov 2022;8:263. [PMID: 35577773 DOI: 10.1038/s41420-022-01057-7] [Reference Citation Analysis]
74 Deng S, Feng Y, Pauklin S. 3D chromatin architecture and transcription regulation in cancer. J Hematol Oncol 2022;15:49. [PMID: 35509102 DOI: 10.1186/s13045-022-01271-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Du D, Xu D, Zhu L, Stazi G, Zwergel C, Liu Y, Luo Z, Li Y, Zhang Y, Zhu K, Ding Y, Liu J, Fan S, Zhao K, Zhang N, Kong X, Jiang H, Chen K, Zhao K, Valente S, Min J, Duan W, Luo C. Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2-EED Interaction. J Med Chem 2021;64:8194-207. [PMID: 34077206 DOI: 10.1021/acs.jmedchem.0c02261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
76 Barazeghi E, Hellman P, Norlén O, Westin G, Stålberg P. EZH2 presents a therapeutic target for neuroendocrine tumors of the small intestine. Sci Rep 2021;11:22733. [PMID: 34815475 DOI: 10.1038/s41598-021-02181-7] [Reference Citation Analysis]
77 Zhang K, Fang T, Shao Y, Wu Y. TGF-β-MTA1-SMAD7-SMAD3-SOX4-EZH2 Signaling Axis Promotes Viability, Migration, Invasion and EMT of Hepatocellular Carcinoma Cells. Cancer Manag Res 2021;13:7087-99. [PMID: 34531686 DOI: 10.2147/CMAR.S297765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Han X, Mo J, Yang Y, Wang Y, Lu H. Crucial Roles of LncRNAs-Mediated Autophagy in Breast Cancer. Int J Med Sci 2022;19:1082-92. [PMID: 35813295 DOI: 10.7150/ijms.72621] [Reference Citation Analysis]
79 Ye M, Gao R, Chen S, Wei M, Wang J, Zhang B, Wu S, Xu Y, Wu P, Chen X, Ma J, Ma D, Dong K. Downregulation of MEG3 and upregulation of EZH2 cooperatively promote neuroblastoma progression. J Cell Mol Med 2022. [PMID: 35257481 DOI: 10.1111/jcmm.17258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Jin M, Duan J, Liu W, Ji J, Liu B, Zhang M. Feedback activation of NF-KB signaling leads to adaptive resistance to EZH2 inhibitors in prostate cancer cells. Cancer Cell Int 2021;21:191. [PMID: 33794893 DOI: 10.1186/s12935-021-01897-w] [Reference Citation Analysis]
81 Huang X, Yang Q, Xie L, Lei S. Histone methyltransferase enhancer of zeste 2 polycomb repressive complex 2 subunit exacerbates inflammation in depression rats by modulating microglia polarization. Bioengineered 2022;13:5509-24. [PMID: 35172677 DOI: 10.1080/21655979.2022.2036892] [Reference Citation Analysis]
82 Yang T, Yang Y, Wang Y. Predictive biomarkers and potential drug combinations of epi-drugs in cancer therapy. Clin Epigenetics 2021;13:113. [PMID: 34001246 DOI: 10.1186/s13148-021-01098-2] [Reference Citation Analysis]
83 Zhao Y, Guan Y, Zhao F, Yu T, Zhang S, Zhang Y, Duan Y, Zhou X. Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs. European Journal of Medicinal Chemistry 2022;231:114144. [DOI: 10.1016/j.ejmech.2022.114144] [Reference Citation Analysis]
84 Servidei T, Lucchetti D, Navarra P, Sgambato A, Riccardi R, Ruggiero A. Cell-of-Origin and Genetic, Epigenetic, and Microenvironmental Factors Contribute to the Intra-Tumoral Heterogeneity of Pediatric Intracranial Ependymoma. Cancers (Basel) 2021;13:6100. [PMID: 34885210 DOI: 10.3390/cancers13236100] [Reference Citation Analysis]
85 Wang S, Qian Z, Ge X, Li C, Xue M, Liang K, Ma R, Ouyang L, Zheng L, Jing J, Cao S, Zhang Y, Yang Y, Chen Y, Ma J, Yao B. LncRNA Tug1 maintains blood-testis barrier integrity by modulating Ccl2 expression in high-fat diet mice. Cell Mol Life Sci 2022;79:114. [PMID: 35103851 DOI: 10.1007/s00018-022-04142-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 El Sayed R, El Darsa H. Therapeutic Modalities in Small Cell Lung Cancer: a paradigm shift after decades of quiescence. Expert Opin Pharmacother 2022. [PMID: 35176957 DOI: 10.1080/14656566.2022.2042515] [Reference Citation Analysis]
87 Shi T, Morishita A, Kobara H, Masaki T. The Role of Long Non-Coding RNA and microRNA Networks in Hepatocellular Carcinoma and Its Tumor Microenvironment. Int J Mol Sci 2021;22:10630. [PMID: 34638971 DOI: 10.3390/ijms221910630] [Reference Citation Analysis]
88 Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, Yang W, Tian C, Miao Z, Wang T, Yang S. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther 2021;6:201. [PMID: 34054126 DOI: 10.1038/s41392-021-00572-w] [Cited by in Crossref: 118] [Cited by in F6Publishing: 90] [Article Influence: 118.0] [Reference Citation Analysis]
89 Danishuddin, Kumar V, Parate S, Bahuguna A, Lee G, Kim MO, Lee KW. Development of Machine Learning Models for Accurately Predicting and Ranking the Activity of Lead Molecules to Inhibit PRC2 Dependent Cancer. Pharmaceuticals (Basel) 2021;14:699. [PMID: 34358125 DOI: 10.3390/ph14070699] [Reference Citation Analysis]
90 Chaudhary P, Guragain D, Chang JH, Kim JA. TPH1 and 5-HT7 Receptor Overexpression Leading to Gemcitabine-Resistance Requires Non-Canonical Permissive Action of EZH2 in Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;13:5305. [PMID: 34771469 DOI: 10.3390/cancers13215305] [Reference Citation Analysis]
91 Hu J, Zheng Z, Lei J, Cao Y, Li Q, Zheng Z, Chen C. Targeting the EZH2-PPAR Axis Is a Potential Therapeutic Pathway for Pancreatic Cancer. PPAR Res 2021;2021:5589342. [PMID: 34335707 DOI: 10.1155/2021/5589342] [Reference Citation Analysis]
92 Jing Z, Liu Q, Xie W, Wei Y, Liu J, Zhang Y, Zuo W, Lu S, Zhu Q, Liu P. NCAPD3 promotes prostate cancer progression by up-regulating EZH2 and MALAT1 through STAT3 and E2F1. Cellular Signalling 2022. [DOI: 10.1016/j.cellsig.2022.110265] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Behling F, Fodi C, Gepfner-Tuma I, Kaltenbach K, Renovanz M, Paulsen F, Skardelly M, Honegger J, Tatagiba M, Schittenhelm J, Tabatabai G; International Consortium on Meningiomas. H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort. Neuro Oncol 2021;23:1273-81. [PMID: 33367841 DOI: 10.1093/neuonc/noaa303] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
94 Genco IS, Ozgultekin B, Hosseini H, Hackman K, Ferreira L, Santagada E, Wahl S, Hajiyeva S. High EZH2 expression in ductal carcinoma in situ diagnosed on breast core needle biopsy is an independent predictive factor for upgrade on surgical excision. Pathol Res Pract 2020;216:153283. [PMID: 33197837 DOI: 10.1016/j.prp.2020.153283] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
95 Christensen LM, Hancock WW. Nuclear Coregulatory Complexes in Tregs as Targets to Promote Anticancer Immune Responses. Front Immunol 2022;13:909816. [DOI: 10.3389/fimmu.2022.909816] [Reference Citation Analysis]
96 Li J, Li Y, Wang Y, He X, Wang J, Cai W, Jia Y, Xiao D, Zhang J, Zhao M, Shen K, Li Z, Jia W, Wang K, Zhang Y, Su L, Zhu H, Hu D. Overexpression of miR-101 suppresses collagen synthesis by targeting EZH2 in hypertrophic scar fibroblasts. Burns Trauma 2021;9:tkab038. [PMID: 34859108 DOI: 10.1093/burnst/tkab038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
97 Misawa K, Yamaotsu N, Hirono S. Identification of novel EED-EZH2 PPI inhibitors using an in silico fragment mapping method. J Comput Aided Mol Des 2021;35:601-11. [PMID: 33635506 DOI: 10.1007/s10822-021-00378-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
98 Szabó CL, Szabó B, Sebák F, Bermel W, Tantos A, Bodor A. The Disordered EZH2 Loop: Atomic Level Characterization by 1HN- and 1Hα-Detected NMR Approaches, Interaction with the Long Noncoding HOTAIR RNA. Int J Mol Sci 2022;23:6150. [PMID: 35682829 DOI: 10.3390/ijms23116150] [Reference Citation Analysis]
99 Xiong J, Barayan R, Louie AV, Lok BH. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review. Semin Cancer Biol 2022:S1044-579X(22)00179-1. [PMID: 35917883 DOI: 10.1016/j.semcancer.2022.07.008] [Reference Citation Analysis]
100 Xie Y, Ning S, Hu J. Molecular mechanisms of neuroendocrine differentiation in prostate cancer progression. J Cancer Res Clin Oncol 2022. [PMID: 35633416 DOI: 10.1007/s00432-022-04061-7] [Reference Citation Analysis]
101 Khaddour K, Maahs L, Avila-Rodriguez AM, Maamar Y, Samaan S, Ansstas G. Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches. Cancers (Basel) 2021;13:5847. [PMID: 34831002 DOI: 10.3390/cancers13225847] [Reference Citation Analysis]
102 Qin J, Li Y, Li Z, Qin X, Zhou X, Zhang H, Li S. LINC00114 stimulates growth and glycolysis of esophageal cancer cells by recruiting EZH2 to enhance H3K27me3 of DLC1. Clin Epigenetics 2022;14:51. [PMID: 35414117 DOI: 10.1186/s13148-022-01258-y] [Reference Citation Analysis]
103 Bae A, Jung S, Lee J, Lee H, Park SG. Clinical Value of EZH2 in Hepatocellular Carcinoma and Its Potential for Target Therapy. Medicina 2022;58:155. [DOI: 10.3390/medicina58020155] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Dong B, Qiu Z, Wu Y. Tackle Epithelial-Mesenchymal Transition With Epigenetic Drugs in Cancer. Front Pharmacol 2020;11:596239. [PMID: 33343366 DOI: 10.3389/fphar.2020.596239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Ushio R, Hiroi M, Matsumoto A, Mori K, Yamamoto N, Ohmori Y. Enhanced Cytotoxic Effects in Human Oral Squamous Cell Carcinoma Cells Treated with Combined Methyltransferase Inhibitors and Histone Deacetylase Inhibitors. Biomedicines 2022;10:763. [DOI: 10.3390/biomedicines10040763] [Reference Citation Analysis]
106 Czaja AJ. Epigenetic Aspects and Prospects in Autoimmune Hepatitis. Front Immunol 2022;13:921765. [DOI: 10.3389/fimmu.2022.921765] [Reference Citation Analysis]
107 Yuan JL, Yin CY, Li YZ, Song S, Fang GJ, Wang QS. EZH2 as an epigenetic regulator of cardiovascular development and diseases. J Cardiovasc Pharmacol 2021. [PMID: 34029268 DOI: 10.1097/FJC.0000000000001062] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
108 Schümann FL, Groß E, Bauer M, Rohde C, Sandmann S, Terziev D, Müller LP, Posern G, Wienke A, Fend F, Hansmann M, Klapper W, Rosenwald A, Stein H, Dugas M, Müller-tidow C, Wickenhauser C, Binder M, Weber T. Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas. Biomedicines 2021;9:1842. [DOI: 10.3390/biomedicines9121842] [Reference Citation Analysis]
109 Genco IS, Hackman K, Morrar D, Jin C, Santagada E, Hajiyeva S. The significance of enhancer of zeste homolog 2 (EZH2) expression in spindle cell lesions of the breast. Pathol Int 2021;71:415-9. [PMID: 33730427 DOI: 10.1111/pin.13093] [Reference Citation Analysis]
110 Liu X, Zhang X, Du S. Long non-coding RNA ACTA2-AS1 inhibits the cisplatin resistance of non-small cell lung cancer cells through inhibiting autophagy by suppressing TSC2. Cell Cycle 2022;:1-11. [PMID: 34985374 DOI: 10.1080/15384101.2021.2020433] [Reference Citation Analysis]
111 Barrero MJ. Epigenetic Regulation of the Non-Coding Genome: Opportunities for Immuno-Oncology. Epigenomes 2020;4:22. [PMID: 34968293 DOI: 10.3390/epigenomes4030022] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
112 Zhou B, Liang X, Mei H, Qi S, Jiang Z, Wang A, Zou F, Liu Q, Liu J, Wang W, Hu C, Chen Y, Wang Z, Wang B, Wang L, Liu J, Liu Q. Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas. J Med Chem 2021;64:15170-88. [PMID: 34664960 DOI: 10.1021/acs.jmedchem.1c01154] [Reference Citation Analysis]
113 Gaultier C, Foppolo S, Maurange C. Regulation of developmental hierarchy in Drosophila neural stem cell tumors by COMPASS and Polycomb complexes. Sci Adv 2022;8:eabi4529. [PMID: 35544555 DOI: 10.1126/sciadv.abi4529] [Reference Citation Analysis]
114 Schwartz CJ, Pareja F, da Silva EM, Selenica P, Ross DS, Weigelt B, Brogi E, Reis-Filho JS, Wen HY. Histologic and genomic features of breast cancers with alterations affecting the SWI/SNF (SMARC) genes. Mod Pathol 2021. [PMID: 34079072 DOI: 10.1038/s41379-021-00837-3] [Reference Citation Analysis]
115 Hao A, Wang Y, Stovall DB, Wang Y, Sui G. Emerging Roles of LncRNAs in the EZH2-regulated Oncogenic Network. Int J Biol Sci 2021;17:3268-80. [PMID: 34512145 DOI: 10.7150/ijbs.63488] [Reference Citation Analysis]
116 Xue S, Ma M, Bei S, Li F, Wu C, Li H, Hu Y, Zhang X, Qian Y, Qin Z, Jiang J, Feng L. Identification and Validation of the Immune Regulator CXCR4 as a Novel Promising Target for Gastric Cancer. Front Immunol 2021;12:702615. [PMID: 34322132 DOI: 10.3389/fimmu.2021.702615] [Reference Citation Analysis]
117 Ball HC, Alejo AL, Samson TK, Alejo AM, Safadi FF. Epigenetic Regulation of Chondrocytes and Subchondral Bone in Osteoarthritis. Life 2022;12:582. [DOI: 10.3390/life12040582] [Reference Citation Analysis]
118 Kim HJ, Cantor H, Cosmopoulos K. Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition. Trends Immunol 2020;41:948-63. [PMID: 32976740 DOI: 10.1016/j.it.2020.08.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
119 Gao X, Peng Y, Fang Z, Li L, Ming S, Dong H, Li R, Zhu Y, Zhang W, Zhu B, Liao J, Wang Z, Liu M, Lin W, Zeng J, Gao X. Inhibition of EZH2 ameliorates hyperoxaluria-induced kidney injury through the JNK/FoxO3a pathway. Life Sci 2021;:120258. [PMID: 34952043 DOI: 10.1016/j.lfs.2021.120258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
120 Ren Y, Yan C, Wu L, Zhao J, Chen M, Zhou M, Wang X, Liu T, Yi Q, Sun J. iUMRG: multi-layered network-guided propagation modeling for the inference of susceptibility genes and potential drugs against uveal melanoma. NPJ Syst Biol Appl 2022;8:18. [PMID: 35610253 DOI: 10.1038/s41540-022-00227-8] [Reference Citation Analysis]
121 Stairiker CJ, Pfister SX, Hendrickson E, Yang W, Xie T, Lee C, Zhang H, Dillon C, Thomas GD, Salek-Ardakani S. EZH2 Inhibition Compromises α4-1BB-Mediated Antitumor Efficacy by Reducing the Survival and Effector Programming of CD8+ T Cells. Front Immunol 2021;12:770080. [PMID: 34925340 DOI: 10.3389/fimmu.2021.770080] [Reference Citation Analysis]
122 Xu Y, Li P, Liu Y, Xin D, Lei W, Liang A, Han W, Qian W. Epi‐immunotherapy for cancers: rationales of epi‐drugs in combination with immunotherapy and advances in clinical trials. Cancer Communications. [DOI: 10.1002/cac2.12313] [Reference Citation Analysis]
123 Chen S, Zhao E. Development and validation of a robust epithelial-mesenchymal transition (EMT)-related prognostic signature for hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2021;45:101587. [PMID: 33662631 DOI: 10.1016/j.clinre.2020.101587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]